Study Watch with Irregular Pulse Monitor

The Study Watch with Irregular Pulse Monitor is a prescription wearable system designed for adults with or at risk of atrial fibrillation, enabling them to record heart rhythms and single-channel ECGs under HCP guidance. It utilizes photoplethysmography for continuous irregular pulse detection and electrode-based technology for on-demand ECG capture, with data securely transferred to a cloud platform for healthcare professional review.

The Study Watch with Irregular Pulse Monitor, from Verily Life Sciences, is a prescription wearable device for adult patients (22 years and older) diagnosed with or susceptible to atrial fibrillation. It enables users to monitor and record their heart rhythms, including single-channel electrocardiogram (ECG) data. Intended for use in professional healthcare facility environments while worn as a wristwatch, the device prompts users to take a 60-second ECG, particularly upon detecting an irregular pulse. An animated ECG is displayed on the watch, but the actual waveform is securely transferred for review by a healthcare professional (HCP), without direct patient access to the detailed data on the watch. The device employs photoplethysmography (PPG) for continuous irregular pulse detection and utilizes two dedicated sensing electrodes for on-demand single-channel ECG acquisition when the user creates skin contact. ECG measurements, along with other physiological data, are transferred from the watch via a charging cradle and Verily's Study Hub to a cloud server. HCPs can then view these time-stamped ECG waveforms through a web portal, which does not include analytical features. Clinical studies demonstrated the PPG-based Irregular Pulse Monitor algorithm achieved 85% sensitivity and 96% specificity in detecting irregular pulses when compared against Holter ECG data.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the typical battery life of the Study Watch under conditions of continuous PPG monitoring and frequent ECG captures, and how does this impact user compliance?; How does the device's PPG-based irregular pulse detection algorithm differentiate atrial fibrillation from other common arrhythmias or motion artifacts, especially in ambulatory settings outside of "professional healthcare facility environments"?; What are the specific criteria or thresholds used by the Irregular Pulse Monitor to trigger a notification and recommend an ECG capture, and how were these validated across diverse patient populations?; Given that patients do not have direct access to their ECG waveforms, what mechanisms are in place to ensure timely review by HCPs and subsequent communication of clinically significant findings back to the patient?; What is the observed learning curve and user acceptance rate for both patients (using the watch) and HCPs (using the web portal), particularly concerning the data interpretation workflow without integrated analysis features on the portal?